Alzheimer’s, the American FDA gives full approval to a drug that slows down the disease
[ad_1]
The US Food and Drug Administration has given full approval, for the first time, to a drug that moderately slows Alzheimer’s.
Hopes from a new drug against Alzheimer’s. Slows disease progression by a third
by Valentina Arcovio
The agency previously gave the drug, called Leqembi, a fast-track approval path based on its ability to reduce amyloid clots in the brain, a hallmark of the disease. Subsequent data showed that the drug was able to slow cognitive and functional decline by 27% in 18 months. The drug, which must be administered intravenously every two weeks, is aimed at patients who are in the early stage of Alzheimer’s.
Alzheimer’s, disappointment new drugs: anti-amyloid monoclonals damage the brain
by Valentina Arcovio
The FDA also said it asked the company that makes the drug to include a warning that Leqembi and other members of this new class of anti-amyloid drugs can cause brain swelling and hemorrhage.
[ad_2]
Source link
